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ABSTRACT 
  
Lysyl oxidase like-2 (LOXL2) was found to be present extracellularly in primary human 
gingival fibroblast cells. This project has been primarily focused on investigating our 
hypothesis that LOXL2 may play a critical role in regulating cell proliferation and 
collagen accumulation in primary human gingival fibroblast cells, which may contribute 
to the development of fibrotic changes in human gingival tissue. LOXL2 shRNA 
lentivirus reduced the LOXL2 mRNA and protein expression by 90 – 95%. Knockdown 
of LOXL2 or inhibition of LOXL2 enzymatic activity strongly inhibited both basal and 
CCN2/CTGF-stimulated collagen accumulation (p<0.05). Proliferation assays 
demonstrated a marked decrease in cell proliferation in both the short and long term in 
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LOXL2 shRNA knockdown cells with minimal or no stimulation of cell apoptosis. 
Pharmacologic inhibition of LOXL2 enzyme activity reduced basal and CCN2/CTGF-
stimulated cell proliferation (40% and 50%) in short term cultures. Furthermore, there 
was 15-20% inhibition seen in long term assays.  Recombinant active LOXL2 
significantly increased collagen accumulation and cell proliferation (p<0.05). Thereby, 
our investigation in vitro by loss and gain of function experiments confirmed that LOXL2 
is critically required for both gingival fibroblast proliferation and for collagen 
accumulation in the presence or absence of CCN2/CTGF. LOXL2 stimulation is critical 
for both proliferation and collagen accumulation in primary human gingival fibroblasts. 
Lastly, we found that the presence of LOXL2 extracellularly and LOXL2 may regulate 
cell proliferation by enhancing the phosphorylation of PDGFRβ. 
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1. Introduction  
 
         Drug induced overgrowth or hypertrophy of gingival tissue may occur due to the 
use of the following medications: the anti-epileptic drug phenytoin, which was described 
by Kimball in 1939, the antihypertensive drug nifedipine, which is a calcium channel 
blocker, or the immunosuppressant drug cyclosporine A. A unique feature about the 
drug induced gingival overgrowth is that all these drugs have different mechanisms of 
action, but all of them cause the overgrowth of gingival tissue. In addition, people 
affected by drug induced gingival overgrowth do not have fibrosis anywhere else. This 
indicates that this disease is more tissue specific and may be regulated by a completely 
different signaling pathway (1). 
         In the United States alone this condition affects over 3 million people. Among 
them are 20% of people taking phenytoin, as it is still the drug of choice for individuals 
suffering from grand mal epilepsy (76). Although the clinical appearance of gingival 
overgrowth lesions is similar, our laboratory showed at both the cellular and biochemical 
levels there are differences among different drug induced gingival overgrowth lesions. 
People affected with gingival overgrowth have an increase in the deposition of 
extracellular matrix in their connective tissue, which is sometimes collagenous along 
with a varying percentage of chronic inflammation (86). 
        Studies have shown that cytokines play a critical role in the pathogenesis of drug-
induced gingival overgrowth due to the disruption in the balance of cytokine levels in 
gingival tissue which contributes to the overgrowth. In addition, there is an increase in 
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different cytokine levels like interleukin-6 (IL-6), IL-1β, transforming growth factor-β 
(TGF-β), fibroblast growth factor (FGF), and platelet-derived growth factor - B (PDGFB) 
(4, 37, 62, 64). 
          CTGF/CCN2 is a 38 KDa protein with diverse functions like cell adhesion, 
proliferation, progression of atherosclerosis, skeletal development, tooth development, 
and apoptosis (14, 31, 32, 60, 66, 78, 79). The diagrammatic representation of the CCN 
family is presented in Figure 1. The family consists of six members which are as 
follows: CCN1 (Cyr61), CCN2 (connective tissue growth factor, CTGF), CCN3 (Nov), 
CCN4 (WISP1), CCN5 (WISP2), and CCN6 (WISP3) (13, 61, 72). The structure of 
these matricellular proteins consists of four modules; Module 1: Insulin like growth factor 
binding protein (IGBP), Module 2: von Willebrand factor domain, Module 3: 
thrombospondin domain (TSP), and Module 4: cysteine knot domain (13).  
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Figure 1 Structural representation of CCN family members. 
 
 
 
 
 
 
 
 
 
 
Andrew Leask, David J. Abraham (2006) 
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Figure 1 Representation of the structure of CCN family members  
There are 6 CCN family members CCN1-CCN6. CCN1-CCN5 contain 4 modules which 
are a secretory signal peptide (SP), an IGF-binding domain (Module I), a von Willebrand 
type C domain (VWC, Module II), a thrombospondin-1 domain (TSP-1, Module III), and 
a cysteine knot (Module IV) domain.  CCN6 lacks the cysteine knot region. 
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         CCN2/CTGF levels are up-regulated in a number of fibrotic conditions (46) like 
hepatic fibrosis, (67) idiopathic pulmonary fibrosis, (49) and systemic sclerosis (79). In 
our laboratory upregulation of CCN2/CTGF expression in phenytoin-induced gingival 
lesions was found (84). In addition, our laboratory further showed that CCN2/CTGF 
promotes collagen deposition in human gingival fibroblasts, but does not stimulate 
collagen synthesis (35). This was accompanied by an increase in the enzyme activity of 
LOX (35). Furthermore, the effect of CCN2/CTGF mediated up-regulation of collagen 
deposition is mediated by α6β1 integrin interactions (30).  
        The lysyl oxidase family consists of lysyl oxidase (LOX) and four lysyl oxidase like 
proteins: LOX, LOXL1, LOXL2, LOXL3, and LOXL4. They are all copper-containing 
amine oxidases. These enzymes can oxidize primary amines to aldehydes, thereby, 
acting as catalysts in the cross-linking of extracellular matrix (ECM) (20). Lysyl oxidase 
and its family members are present in the following human genome regions of a human 
chromosome: lysyl oxidase on chromosome 5q23.3-31.2, lysyl oxidase like-1 on 
chromosome 15q24-25, Lysyl oxidase like-2 on chromosome 8p21.2-p21.3, lysyl 
oxidase like-3 on chromosome 2p13, and lysyl oxidase like-4 on chromosome 10q24. 
(3, 28, 38, 42). 
        Structural representation of LOX and its family members are present in Figure 2. 
Structural differences among these proteins are present in their N-terminal region (57). 
All members have a copper-binding motif, lysyl tyrosyl quinone (LTQ) residues, and a 
cytokine receptor-like domain located in the highly conserved carboxyl (C)- termini. 
LOXL2, LOXL3, and LOXL4 have four SRCR domains (scavenger receptor cysteine-
rich domains) in the N-terminal regions (44) and have similar structure on the other 
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hand LOX and LOXL1 are found to be structurally similar. Furthermore, LOX and 
LOXL1 are structurally different from LOXL2, LOXL3 and LOXL4.  Lysyl oxidase (LOX), 
as mentioned earlier, is an amine oxidase. Its primary function is to post-translationally 
modify collagen and elastin present in the extracellular matrix by catalyzing the 
oxidative deamination of the lysine residue which is required for subsequent collagen 
cross-linking (20, 39). 
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Figure 2   Structural representation of LOX family members. 
 
 
 
 
 
 
 
 
Holly E. Barker, Thomas R. Cox & Janine T. Erler (2012) 
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Figure 2.  Structural representation of LOX and its other family members  
The LOX family consists of 5 members; LOX and LOXL 1- 4. All LOX family members 
have a similar and highly conserved C-terminal region consisting of a Cu binding site, 
LTQ (lysyl tyrosyl quinone), and CRL (cytokine receptor like domain). The N- terminal 
region varies.  LOXL2, LOXL3, and LOXL4 have a similar SRCR, whereas LOX and 
LOXL1 consist of a propeptide region.  
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         It is shown that LOXL2 can oxidize lysine residues of collagen.  Its role in cross-
linking is similar to LOX in that respect (20, 85).  
         A study done in 2015 in our laboratory showed up-regulation of LOXL2 in human 
phenytoin induced gingival overgrowth samples (2). LOXL2 is one of the most studied 
members of the LOX family, apart from LOX. LOXL2 is a multifunctional protein with 
different intracellular and extracellular functions such as proliferation, cell migration, 
adhesion, EMT, angiogenesis, cell polarity, upregulating metastasis, and differentiation 
(6, 10, 16, 34, 59, 70, 71). In vitro studies in the past have shown the presence of 
LOXL2 extracellularly (22, 34, 85), intracellularly, (22, 34) and also localized in the 
perinuclear compartment (69). The molecular weight of 75-kDa LOXL2 was detected in 
the cytosol of MDA-MB-231 cells and MCF-7 cells possibly due to re-internalization of 
secreted LOXL2 (52). Furthermore, the presence of active secreted LOXL2 in MCF-7 
cells was at 100-kDa and was found to be N-glycosylated at Asn-455 and Asn-644, 
whereas intracellular LOXL2 (75 kDa) was found to be N-terminally processed and non- 
glycosylated.  Intracellular LOXL2 was strongly associated with EMT.  Secreted LOXL2 
(extracellular) was found to be associated with being invasive in vitro (58).  
        LOXL2 is considered to play a critical role in promoting fibrosis (1, 40, 54). Studies 
in the past have shown that LOXL2 is upregulated in different fibrotic diseases like 
Wilson’s Disease and Primary Biliary Cirrhosis, (85). Up-regulation of LOXL2 was found 
in mice models affected with the progressive liver disease known as chronic cholangitis.  
This is very similar when compared to human primary sclerosing cholangitis (63). A 
study by Vadasz reported the previous findings regarding liver fibrosis and concluded 
that the upregulation of LOX and LOXL2 could be leading to liver damage.       
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Furthermore, LOX and LOXL2 may be used as a potential diagnostic tool in future (85).  
In addition, LOXL2 appears to have a role in cell proliferation (85). LOXL2 was found to 
promote cell proliferation and inhibit apoptosis in breast carcinoma cells (43). In another 
study by Chang it was also shown that an increase in LOXL2 led to an increase in cell 
proliferation in MCF10A mammary cells (17). Furthermore, a study by Lin showed that 
the common effects of CAF (cancer-associated fibroblasts) on HCC (hepatocellular 
carcinoma cells) to promote proliferation, migration, and invasion of cancer cells is 
promoted by 10 genes and LOXL2 is among them (50). LOXL2 has also been found to 
upregulate cell proliferation and migration in human umbilical endothelial cells (10). 
Another critical role of LOXL2 has been found in up-regulation of metastasis.  
        Up-regulation of LOXL2 has been observed in cancers of the esophagus, prostate, 
pancreas, head and neck, and bile ducts. In addition, LOXL2 expression has been 
associated with more aggressive colon, gastric, breast cancers, and oral squamous cell 
carcinoma (6, 22, 45, 53, 70, 71). LOXL2 upregulates EMT in carcinoma of the 
pancreas as well (75).  LOXL2 has been shown to play a role in upregulating EMT, 
tumor invasion, angiogenesis, and remodeling of the microenvironment, suggesting that 
LOXL2 may be a potential therapeutic target for the prevention of metastatic diseases 
(6).  
        The major goal of this study was to determine whether LOXL2 regulates cell 
proliferation and collagen accumulation in primary gingival fibroblasts in both the 
presence and absence of CCN2/CTGF and the mechanism by which it is regulated. 
Studies in the past have shown the presence of increased levels of platelet derived 
growth factor (PDGF) during wound healing and fibrosis (19, 27). Studies have shown 
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that PDGF-α and -β receptors are stimulated in human gingival fibroblasts and 
periodontal ligament cells during its repair (27, 68). In addition, a study by Iacopino et al. 
in 1997 showed there was a marked increase in the level of PDGF-B among individuals 
effected by phenytoin-induced gingival growth (37).  
        The PDGF family consists of four homodimers: PDGF-AA, PDGF-BB, PDGF-CC, 
and PDGF-DD and one heterodimer PDGF-AB (8, 9). PDGF was first isolated from 
human platelets and the molecular weight of the protein was found to be between 28–
31 kDa (33). PDGF stimulates multiple cellular functions like cell proliferation and 
migration through membrane receptors of the tyrosine kinase family and angiogenesis. 
PDGF-A only binds to the PDGF-α receptor, whereas PDGF-B can bind to both α and β 
receptors. Once the PDGF binds to its receptors, it activates a variety of signaling 
pathways, such as Akt/PKB and ERK, and promotes cell migration, proliferation, and 
extracellular matrix synthesis (21, 29, 74, 81). 
        PDGF regulates cellular functions by phosphorylation followed by activation of 
signal transduction pathways, which are regulated further at different stages by 
activation of cell-surface receptors.  
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2. AIM 
 
        The major goal of this present study was to determine whether LOXL2 expression 
plays a critical role in regulating collagen deposition and cell proliferation both in 
CCN2/CTGF stimulated and non-stimulated primary human gingival fibroblasts and to 
determine the mechanism by which cell proliferation is regulated.  
1) Determine if LOXL2 is a key biological mediator in regulating cell 
proliferation in human gingival fibroblasts in vitro. 
• Determine the effect of inhibition of LOXL2 expression on proliferation 
(short and long term) in primary human gingival fibroblasts in the presence 
and absence of CCN2/CTGF. 
• Determine the effect of addition rLOXL2 on proliferation. 
• Determine the mechanism which may regulate cell proliferation. 
 
2) Determine if LOXL2 is a key biological mediator in regulating collagen 
accumulation in human gingival fibroblasts in vitro. 
 
• Determine the effect of inhibition of LOXL2 expression on collagen in 
primary human gingival fibroblasts in the presence and absence of 
CCN2/CTGF. 
• Determine the effect of the addition of LOXL2 on collagen accumulation. 
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3. Materials and Methods 
 
3.1 Cell Culturing 
 
         Gingival tissues were obtained from the Boston University Henry M. Goldman 
School of Dental Medicine from the Department of Periodontics. Gingival tissues were 
taken from three healthy adult subjects between 25 - 35 years of age undergoing crown 
lengthening procedures. The protocol for procuring human gingival tissue from subjects 
were fully approved by a Boston University Medical Center IRB committee. Gingival 
tissue samples were collected in tubes containing Dulbecco’s phosphate buffer solution 
(PBS) along with 10% penicillin/streptomycin. Samples were washed in PBS with 
penicillin/streptomycin 5 times. De-epithelized samples were cultured in 10 cm culture 
plates containing DMEM (Dulbecco’s Modified Eagle’s Medium) containing 10% Heat 
Inactivated fetal bovine serum (HI-FBS), 0.1mM non-essential amino acids, and 
antibiotics (penicillin/streptomycin) for 7 days. Medium was changed to DMEM 
(Dulbecco’s Modified Eagle’s Medium) containing 10% Fetal Bovine Serum (F-0926), 
0.1 mM non-essential amino acids, and 1% penicillin/streptomycin after 7 days. Media 
was changed once every week for 3 weeks. After 3 weeks, fibroblast cells were 
passaged. After the second passage, cell stocks were made and stored in liquid 
nitrogen. For the experiments, cells were grown from frozen stocks in 10 cm2 cell culture 
plates and were less than passage 7. Cells were cultured at 37 °C in 5% CO2 
atmosphere in DMEM (Dulbecco’s Modified Eagle’s Medium) containing 10% fetal 
bovine serum (FBS - 0926), 0.1mM non-essential amino acids, and 1% penicillin/ 
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streptomycin and grown to 80% confluence. Gingival fibroblast cell cultures were 
transduced with lentivirus at 25 (MOI) for 16 hours (LOXL2shrna —193,195, Non target 
shRNA) and were selected with puromycin (0.5 µg/ml). The stable cells were seeded in 
6 well plates and triplicates for each condition were used for the experiment. Then cell 
layer extracts were collected and analyzed for protein expression of LOXL2 via Western 
Blot.  
         To determine whether the expression of LOXL2 is inhibited at the mRNA level 
fibroblasts were cultured in a 10 cm plates, grown to 80% confluence, transduced with 
lentivirus (LOXL2shrna — 193, 195, Non target shRNA), and selected with puromycin 
(0.5 µg/ml). The stable cells were seeded in 6 well plates as described for each 
experiment. 
         To determine whether the expression of LOXL2 is inhibited at the mRNA level 
fibroblasts were cultured in a 10 cm plate, grown to 80% confluence, transduced with 
lentivirus (LOXL2shRNA — 193, 195, Non target shRNA), cells were selected with 
puromycin, (0.5 µg/ml) and total RNA samples were collected and analyzed for gene 
expression changes via qPCR and western blotting                            
 
3.2 Production of Lentivirus  
 
Experiments using the lentiviruses were performed in the BL2 building. 
 
3.2.1 Transformation 
 
         E. coli is used for transformation because it is highly efficient. The One Shot® 
OmniMAX™ 2-T1RChemically Competent E.coli kit (Cat.No.C8540-03; Life 
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Technologies), S.O.C. Medium, OmniMAX™ 2-T1R cells, and pUC19 Control DNA were 
used for this experiment. In order to perform this experiment, the temperature of the 
water bath was kept at 42°C.  Both the vial of S.O.C medium and LB medium containing 
50 µg/ml ampicillin were used at room temperature. The selective LB agar plates 
containing 200 µl of a 5 mg/ml stock of ampicillin were warmed in the incubator for 30 
minutes at 37°C. One Shot®OmniMAX™ 2-T1R vials of competent cells were thawed on 
ice.  
          In order to perform this experiment 5 µl of DNA from each pcMV-VSV-G, pCMV-
dR8.2 dvpr, were added into respective One Shot® OmniMAX™ 2-T1R vials along with 
either 5 µl of human Non target in HIV lentiviral vector with puromycin (Sigma-Aldrich, 
SHC002) or human LOXL2 (195- TRCN0000046195) or (193-TRCN0000046193, TRC-
2AAG33-E8) followed by gentle mixing.  
         Vials were then incubated on ice for 30 minutes. This was followed by subjecting 
the samples to heat-shock for 30 seconds at 42°C. After 30 seconds vials were taken 
out and placed on ice for 2 minutes. 400 µl of S.O.C. medium was added to each vial 
and vials were incubated for 1 hour at 37°C at 225 rpm in the shaking incubator. 
Samples were then diluted 1:50 into LB medium. 25 µl of each diluted sample were 
spread on respective pre-warmed LB agar plates, inverted, and incubated overnight at 
37°C. Next day, one of the colony was selected from each LB agar plate and added to 
each flask containing 250 ml LB and 125 µl ampicillin (100 mg/ml). Flasks were placed 
for 18 hours at 37 °C on a horizontal shaker at 225 rpm. 
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3.2.2 Isolation of Plasmid 
 
         Isolation and purification of plasmid DNA from transformed competent bacteria 
was done. For the experiment the HiSpeed Plasmid Maxi kit (Cat. No. 12663; Qiagen) 
was used and it contained HiSpeed Maxi tips, QIAfilter Maxi cartridges, QIAprecipitator 
Maxi modules, syringes, reagents, and buffers. Plasmid isolation of each plasmid 
(pcMV-VSV-G, pCMV-dR8.2 dvpr, LOXL2shRNA 195, LOXL2shRNA193, Non-Target 
shRNA control vector, Sigma-Aldrich, SHC002) was performed. 50 ml of media was 
pipetted out of the LB flask containing the transformed competent cells and centrifuged 
at 3,500 rpm for 10 minutes at 4°C. The bacterial pellet was suspended in 20 ml Buffer 
P1. This was followed by addition of 10 ml of Buffer P2 sand incubated for 5 minutes at 
room temperature. Following incubation, 10 ml of Buffer P3, which was chilled on ice, 
was added and mixed well and then centrifuged at 3,500 rpm for 10 minutes at 4°C. 
Bacterial lysate was then put into the barrel of the QIA filter cartridge and incubated for 
5 minutes at room temperature (15-25°C). 10 ml of buffer QBT and was allowed to run 
through. QIAGEN-tip was then washed with 60 ml buffer QC. DNA was eluted with 15 
ml of buffer QF. DNA was precipitated by the addition of 10.5 ml of isopropanol to the 
DNA which was eluted, mixed and incubated for 5 minutes. Eluted sample mixtures 
were filtered through the QIA precipitator. The QIA precipitator was attached again and 
2 ml of 70% ethanol was added to the syringe. The DNA was washed by ethanol 
through the QIA precipitator. This was followed by removal of the QIA precipitator from 
the 30 ml syringe. The QIA precipitator was reattached to a 30 ml syringe and a plunger 
was inserted. The outlet nozzle of the QIA precipitator was dried with absorbent paper. 
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The outlet of the QIA precipitator was put over a collection tube and 1 ml of TE buffer 
was added to the syringe and plunger was inserted. The eluted DNA was collected in a 
1.5 ml tube. The elute was then transferred to the 5 ml syringe again and re-eluted into 
the same 1.5 ml tube. Each plasmid DNA was quantitated using a Nano Drop 
spectrophotometer. Once the quantification was done purification of the plasmid DNA 
was verified by performing a restriction digestion and agarose gel electrophoresis. 
 
3.2.3 Transfection  
 
          293T cells were used for the transfection (as it has high efficacy) which was 
followed by collection of viral particles. 
   On day 0, 293T cells were seeded at a density of 2 x 106 cells in 10 cm2 cell 
culture plates which were coated with gelatin containing 10 ml of Dulbecco’s Modified 
Eagle Medium with 10% fetal bovine serum, (Cat. No. F0926 from Sigma) and 1% 
penicillin/streptomycin (Cat. No.11965-118; Gibco). After 24 hours, the cells were 
treated with three plasmids, respectively. Each plate either contained 24 µg of LOXL2 
(195), 3 µg of pCMV-VSV-G, 24 µg of pCMV-dR8.2 dvpr at a ratio of 8:1:8 or 24 µg of 
LOXL2 (193), 3 µg of pCMV-VSV-G, 24 µg of pCMV-dR8.2 dvpr at a ratio of 8:1:8 or 24 
µg of Non target, or 3 µg of pCMV-VSV-G, 24 µg of pCMV-dR8.2 dvpr at a ratio of 
8:1:8. All three plates were then co-transfected with 150 µl of FuGENE 6 
(Cat.No.05061377001; Roche). On day 3, media from the plates were changed and 15 
ml media was added. On days 4, 5, and 6, the supernatant was collected and stored at 
4°C. The supernatant with the viral particles that was collected for 3 consecutive days 
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was then concentrated using ultrancentrifuge at 18,500 rpm for 1 hour and 30 minutes.  
The supernatant was removed and lentivirus pellets were re-suspended in 200 µl/tube 
of Dulbecco’s Phosphate-Buffered Saline (Cat.No.14190-250; Gibco) and stored at -
80°C. The quantification of viral titer was determined by using p24 ELISA (Cell Biolabs, 
Inc., San Diego, CA). 
 
3.2.4 Quantitation of the Lentiviral particles  
 
        Lentiviruses are quantitated using the QuickTiter™ HIV. Lentivirus Quantitation Kit 
(HIV p24 ELISA) was procured from Cell Bio-labs (VPK-108-HIV-P24). By quantifying 
the viral particles, we can determine the multiplicity of an infection which is indicative of 
the number of viral particle per cell. For this experiment we followed the company 
protocol.  
         In the experiment we used 110 µl of each sample and standards were added to 
the anti-p24 antibody coated plate. The plate was then covered and was incubated at 
37 °C overnight.  The following day wells were emptied and the microwell strips were 
washed 3 times with 250 µl of 1x wash buffer per well and all the excess buffer was 
removed from the micro well strips. 100 µl of Diluted FIT-conjugated anti-p24 
monoclonal antibody was added in every well and was incubated for 1 hour. Once the 
well was emptied it was washed again for another 3 times with 1x wash buffer. 100 µl of 
Diluted HRP-conjugated anti-FITC monoclonal antibody was added to each well and 
was incubated again for another 1 hour. Once again the wells were washed 3 times. 
        100 µl of substrate solution was added to each well. The plate was incubated at 
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room temperature for 20 minutes. 100 µl of the stop solution was added to each well to 
stop the reaction. Absorbance from each well were recorded. Then quantification of 
lentiviral particles were performed. 
 
3.3 Western blot  
 
        10% and 8% SDS-PAGE gels were loaded with equal amounts of protein 
according to the NanoOrange quantitation. Two protein standards were loaded. 12 µl of 
Kaleidoscope (Bio-Rad, 161-0324) and 12 µl of SDS-PAGE Broad range (Bio-Rad, 161-
0318). The gels were run for 2 hours at 70 V. PVDF membranes were used for the 
experiment. Gels were removed from the electrophoresis chamber and placed between 
the membrane, blotting papers, and sponge for transfer. The blot ran overnight in 
blotting buffer at 65 mA. The following day, the membranes were washed with TBS-T 
(made by the lab) 3 times for 10 minutes. The membrane was then blocked with 5% 
nonfat dry milk in TBST (1 gm/20 ml, made in the lab) for 2 hours on a horizontal shaker 
at room temperature. Gel were incubated with primary antibody overnight at 4°C on a 
horizontal shaker with gentle shaking.  A primary antibody used for the samples 
containing LOXL2, which was an anti-hLOXL2 purified rabbit monoclonal antibody (Cat. 
No. GTX-105085), was diluted 1:1000 & a secondary antibody was diluted 1:2000. The 
next day the membranes were washed for 10 minutes with TBS-T 3 times on a 
horizontal shaker. Then the membranes were incubated with the secondary antibody for 
2 hours at room temperature on a horizontal shaker with gentle agitation. The 
membranes were then rinsed with TBS-T 3 times for 10 minutes per rinse and bands 
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were visualized with Immobilon Western Chemiluminescent HRP Substrate (Cat. No. 
E2400; Denville Scientific). Films were developed in the dark room and analyzed using 
the Versadoc.  Membranes were subsequently stripped using Restore Western Blot 
Stripping Buffer (Thermo Scientific, 21059) and then re-probed for loading controls as 
indicated. β-actin (13E5) rabbit mAb (Cell Signaling, 4970L) was the primary antibody 
and anti-rabbit IgG HRP-linked antibody (Cell Signaling, 7074S) was used as the 
secondary antibody. Radiographs were quantified using the Versadoc. 
        For the western blot, using serum free media, serum free conditioned media was 
concentrated down from 10 ml to 250 µl using Amicon Ultra-15, PLQK Ultracel 
Membrane (Cat. No. UFC905024; Millipore). Media was then collected in 15 ml tubes 
and were centrifuged at 3,000 rpm in cell culture centrifuge for 3-5 minutes which 
helped pellet the cells.  Following this, 4.75 ml media was put into Amicon Ultra-15, 
PLQK Ultracel Membrane and was centrifuged in the ultracentrifuge at 7,500 rpm for 7- 
10 minutes at 4°C. The flow through was discarded and the process was repeated till 
the medium was concentrated to 250 µl. This was done for media collected from 
CTGF/CCN2 treated and non-treated groups.  Triplicates for each condition were used. 
Once the media from different samples was concentrated they were collected and 
stored in -20°C. Twenty µg of samples was mixed with sample buffer and 6X loading 
dye, then the samples were boiled for 5 minutes. Western blot was performed. Samples 
were probed for the presence of LOX and all its family members in media. Primary 
antibody used for the samples containing LOX (ab31238), LOXL1 (ab87748), LOXL2 
(Cat. No. GTX-105085), LOXL3 (ab122263), and LOXL4 (ab88186) were diluted 1:1000 
and secondary antibody was diluted 1:2000. The membranes were then rinsed with 
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TBS-T 3 times for 10 minutes per rinsing and bands were visualized with Immobilon 
Western Chemiluminescent HRP Substrate (Cat. No. E2400; Denville Scientific). Films 
were developed in the dark room and analysis was performed using the Versadoc. 
Membranes were subsequently stripped using Restore Western Blot Stripping Buffer 
(Thermo Scientific, 21059) and then re-probed for loading controls as indicated. 
Radiographs were quantified using the Versadoc 3000 imaging system with the 
Quantity One software (Bio-Rad). 
 
3.4 Real time qPCR 
 
         Primary human gingival fibroblasts were seeded in 10 cm2 plates. Once the cells 
were 70% to 80% confluent each plate was transduced with LOXL2shRNA195, 
LOXL2shRNA193, Non Target shRNA respectively for 16 hours. After 16 hours, media 
was replaced by fresh media and 0.5 µg/ml puromycin for 72 hours to select for the 
transduced cells. After 72 hours, RNA RNeasy® Mini kit (Qiagen, Valencia, CA) was 
used according to the manufacturer's instructions to isolate RNA from the transduced 
plates and from a control group in which the fibroblasts were not transduced. Culture 
media was aspirated completely from culture plates, cells were disrupted by addition of 
buffer RLT, and the cell layer was collected. The cell lysates were put in a Qiashredder 
spin column directly, a collection tube was placed, and centrifuged at maximum speed 
for 2 minutes. 70% Ethanol was added to the homogenized lysate and mixed well. The 
sample was then transferred into an RNeasy spin column for RNA binding followed by 
washing with buffer RW1 and buffer RPE. Bound RNA was eluted in RNase-free water. 
RNA samples were collected and stored at −80 °C. RNA was quantified via 
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spectrophotometry (NanoDrop). Once the cDNA was isolated samples were stored at 
−20 °C prior to use in real-time PCR. Two µl of each reverse transcription reaction was 
used for 25 µl of real-time qPCR reaction (12.5 µl of Taqman Universal PCR master 
mix, 1.25 µl specific primer, and 2 µl of template) using the 96-well format. TaqMan 
probe sets (Applied Biosystems, Foster City, CA) employed were for human LOXL2, 
18S rRNA which was our loading control. 
                                               
3.5 CyQUANT Assay 
 
        The CyQUANT cell proliferation assay was used to measure the cell proliferation 
by measuring the fluorescence; which measures the amount of DNA. In this experiment 
primary human gingival fibroblast cells were transduced with either Non Target shRNA, 
LOXL2shRNA195 or LOXL2shRNA193 cells were selected with puromycin (0.5 µg/ml). 
For this experiment 5,000 cells transduced with either lentivirus mentioned above were 
seeded in 24-well plates in the presence and absence of CTGF/CCN2 (200 ng/ml). Next 
day the media was removed and one of the plates was washed with PBS & plates were 
frozen at -80.  For measurement purposes the plates were thawed at room temperature 
and CyQUANT GR dye/cell lysis buffer (Molecular Probes) was added. Samples were 
incubated in the dark for 5 minutes at room temperature. Following the incubation, 200 
µl volume of cell suspension, including standards, was added to wells of a black 
fluorescent microtiter plate (Thermo Fisher Scientific, UK) and fluorescence of the 
samples was measured with a TriStar LB 941 (Berthold Technologies) with excitation at 
480 nm and emission detection at 520 nm. In order to establish that there were the 
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same number of cells in the control and knock-down the number of cells at this point 
was designated as Day 0. Once it was confirmed that the number of cells were the 
same under all conditions a CyQUANT assay was done 24 later. For each condition 6 
replicates were used and each experiment was done with 3 different subjects. 
 
3.5.1 Short-term cell proliferation assay  
 
         The CyQuant cell proliferation reagent assay (C7026) from Invitrogen was used to 
measure short term cell proliferation. Freshly transduced cell with either LOXL2 
shRNA195, LOXL2shRNA193, or Non target shRNA were selected with 0.5 µg /ml. 
Once the cells were selected the cells were seeded at a density of 5,000 cells per well 
in each of 24-well plates per experimental group. On the following day the media was 
removed from four wells and washed with PBS and stored at -80 oC (Day 0). After 24 
hours, media was removed from the remaining four 24-well plates, washed with PBS, 
and plates stored at -80oC. For measurement purposes plates were thawed at room 
temperature for 30 minutes and 200 µl of CyQUANT GR dye/cell lysis buffer (Molecular 
Probes) was added and gently mixed. Samples were incubated in the dark for 5 min at 
room temperature. Following incubation, a 200 µl volume of cell suspension, including 
standards, were added to wells of a black fluorescent microliter plate 11 (Thermo Fisher 
Scientific, UK) and the fluorescence of samples were measured with a TriStar LB 941 
(Berthold Technologies) with excitation at 420 nm and emission detection at 535 nm.  
 
 
		
24	
3.5.2 Long term cell proliferation assay 
 
         Primary gingival fibroblast cells were transduced with either LOXL2 shRNA 
(195,193) or Non target shRNA. The cells were seeded at the density of 5000 cells per 
well in 24-well plates. The attached cells were counted the next day. Cells were 
detached by trypsin-EDTA and were counted using a haemocytometer and CyQUANT 
assay. This time point was considered Day 0 in order to establish that the same number 
of cells in both the control and knock-down group at the beginning of the experiment 
were equivalent. The cells were treated with or without CCN2/CTGF (200 ng/ml). 
CCN2/CTGF (200 ng/ml) and fresh media containing 5% FBS (0926) was added every 
other day for 7 days. Cells in triplicate wells for each condition were then counted using 
a haemocytometer each day and CyQUANT assay was done each day measuring the 
cell proliferation by measuring the fluorescence. Both the cell counting and CyQUANT 
were performed every day for the remainder of the 7 days. We developed a standard 
curve for the CyQUANT assay so the amount of DNA accumulation could be converted 
to a cell number. The number of cells as result of cell counting and CyQUANT assay 
were plotted to compare the growth curve of shLOXL2195 or shLOXL2193 and 
shNonTarget cells in the presence and absence of CCN2/CTGF. 
                             
3.6 Amplex Red Assay 
 
        This assay was performed to measure enzyme activity of LOXL2. Three buffers 
were prepared Buffer 1, Buffer 2, and Buffer 3. Composition of buffer 1 consisted of 50 
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mM borate and 1.2 M urea (pH of 8.2), buffer 2 consisted of 50 mM of borate and 6 M 
urea (pH of 8.2), and buffer 3 contained 50 mM borate with a pH of 8.2. Horseradish 
peroxidase was prepared at a concentration of 170 units/ml, cadaverine 200 mM, 10 
mM BAPN, 10 mM PXS-5033A and 8.7 µM hydrogen peroxide and 1mM Amplex Red 
Reagent (Cat. No. A12222; Life Technologies) Triplicates were prepared for all samples 
and standards. For each sample one set of triplicates were to contain BAPN or PXS-
5033A and for the control no BAPN or PXS-5033A with or without rLOXL2 (10 mM). For 
those containing BAPN or PXS-5033A the buffers were made in the following order: 
379.5 µl of buffer 1-3.0 µl of HRP, 12.5 µl of buffer 2 -25 µl of BAPN, or 2 -25 µl of PXS-
5033A 25 µl of cadaverine, 2-25 µl rLOXL2 and 5 µl of amplex red. A master mix was 
prepared and 450 µl from the master mix was pipetted into each glass tube along with 
50 µl of samples added. For those triplicates not containing BAPN or PXS-5033A, the 
buffers were added in the following sequence - 404.5 µl of buffer 1-3 µl of HRP, 12.5 µl 
of buffer 2 - 25 µl of cadaverine, 2-25 µl rLOXL2 and 5 µl of amplex red. Once the 
master mix was prepared, 450 µl of master mix was pipetted in glass tubes and 50 µl 
samples added respectively. Samples were then incubated for 30 minutes at 37°C. 
Standards were prepared at different concentrations of hydrogen peroxide. Standards 
were prepared as a master mix. Samples were added in the following order of buffers: 
buffer 1, HRP, cadaverine, and Amplex Red. Lastly, hydrogen peroxide was added to 
the tubes. Standards were incubated for 5 minutes at 37 °C. After 30 minutes incubation 
the tubes were placed on ice to stop the reaction. 200 µl from each tube was put in a 
black non-binding 96 well plate. Amplex Red dye reacts with hydrogen peroxide and 
emits fluorescence. The amount of fluorescence emitted from each sample was 
		
26	
recorded using a Berthold Tri Star LB 941 plate reader. This technique measures the 
amount of hydrogen peroxide present in each sample, which is indicative of lysyl 
oxidase-like 2 enzyme activity.  
        Furthermore, in this experiment for the standards H2O2 was added. A standard 
was plotted according to read outs for various concentrations of hydrogen peroxide.  For 
every sample the hydrogen peroxide produced was subtracted from the samples with 
BAPN and PXS-5033A. Results were calculated in nM hydrogen peroxide produced 
according to the equation. Lysyl oxidase like-2 enzyme activity levels were calculated in 
nmoles/µg in 30 minutes in order to determine whether the LOXL2 was active or not. 
 
3.7 Addition of exogenous LOXL2 and its impact on primary gingival fibroblasts 
 
         To evaluate the effect of exogenously added LOXL2 on cell proliferation, primary 
gingival fibroblast cells were seeded at a density of 5,000 cells per well in each of eight 
24-well plates per experimental group and cells were grown under standard cell culture 
conditions. On the following day media was removed from four wells and washed with 
PBS and then stored at -80o C (Day 0). On day 0, Amplex red assay was performed and 
rLOXL2 (0,1 or 2 µg) were added to the samples in a serum free media for 24 hours. 
After 24 hours, media was removed from the remaining four 24-well plates, washed with 
PBS, and plates stored at -80o C. For measurement, plates were thawed at room 
temperature for 30 minutes and 200 µl of CyQUANT GR dye/cell lysis buffer (Molecular 
Probes) was added and gently mixed. Samples were incubated in the dark for 5 minutes 
at room temperature. Following incubation 200 µl volume of cell suspension, including 
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standards, were added to wells of a black fluorescent microliter plate 11 (Thermo Fisher 
Scientific, UK) and the fluorescence of samples was measured with a TriStar LB 
941(Berthold Technologies) with excitation at 420 nm and emission detection at 
 535 nm.  
 
3.8 Caspase 3 activation assay 
 
         Primary gingival fibroblast cells freshly transduced with two different LOXL2 
shRNA lentivirus particles (LOXL2shRNA - 195 and LOXL2shRNA -193) or with Non 
target shRNA were grown in 10 cm plates and at 80% confluence extracted for Western 
blotting. In addition, a positive control for caspase activation which consisted of non-
transduced primary gingival fibroblasts were subjected to 20 Gy of ionizing radiation as 
previously described by Slee in his article in 2001. The corresponding negative control 
were non-irradiated cells grown at the same time. Cell layers were extracted into 
sample buffer (0.5 M Tris pH 6.8, glycerol 10% SDS, 5% β-mercaptoethanol), boiled for 
5 minutes, and stored at -20o C. Nano orange was performed for protein quantification. 
Once the samples were quantified they were subjected to western blotting for activated 
caspase 3.  β-Actin was used as the loading control. 
 
3.9 PDGFRβ and PDGF western blot analysis 
 
        Gingival fibroblasts were grown in 6-well plates to 80% confluency. Cells were 
obtained from 3 different subjects. The medium was changed into serum free media 
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containing either specific LOXL2 inhibitors PXS-5033A (Pharmaxis) 1 µΜ, BAPN 5 µM, 
rLOXL2 1 µM, or control. The serum free medium was changed to serum free media 
with or without PDGF-BB 25 ng/ml for 2 hours. Samples were collected and quantified 
using Nano orange technique. Equal amounts of protein were loaded and western blot 
analysis was performed. PDGFRβ and β - actin were used as loading controls. 
 
3.10 Sirius Red Assay  
 
         Sirius Red dye binding assay was performed for measuring collagen accumulation 
in primary gingival fibroblasts. Once the plates were grown to 100% confluence they 
were grown for an additional 7 days before initiating the treatment protocols. After 7 
days the treatment media was changed with 0.05 mg/ml of ascorbate and treated either 
with pharmacological inhibitor PXS-5033A (0.2 µM, 1 µM and 5 µM) or Recombinant 
active LOXL2 (200 ng/ml, 1 µg/ml and 2 µg/ml) and different concentrations were added 
to each well. Following the next 7 days of the treatment period media were removed 
and cell layers were washed 3 times with PBS. The cell layers were fixed with Bouin’s 
solution (Sigma- HT10132) for 1 hour at room temperature. The solution was removed 
and the plates were washed in running tap water until the yellow stain was removed. 
Plates were dried in the hood overnight. Next day Sirius red dye (Chroma-Germany, 
Sirius Red F3BA) was dissolved in picric acid and for the experiment Sirius dye was 
added to the wells at the concentration of 1 mg/ml for 1 hour at room temperature and 
plates were placed on the shaker under mild shaking. Sirius dye was removed and wells 
were washed four times with 2 ml 0.01 N of HCl to removed unbound dye. The bound 
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dye in each well was eluted with 1 ml of 0.1 N NaOH under mild shaking 30 minutes. 
Optical density was then measured at 550nm using 0.1N sodium hydroxide as a blank. 
Each treatment condition consisted of three wells (n=3) and each experiment was done 
with 3 different subjects to provide sufficient statistical power for these studies.    
 
3.11 Statistical Analysis  
 
        Student t-test and two-way ANOVA with Bonferroni post-tests were performed 
using GraphPad Prism (San Diego) software version 5.02 for Windows; data was 
considered significant at (p<0.05). 
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4. Results 
 
4.1 CCN2/CTGF regulates LOXL2 protein expression in human gingival 
fibroblasts.  
The purpose of our experiment was to analyze whether CCN2/CTGF upregulates the 
expression of LOXL2. Our laboratory recently showed that LOXL2 is expressed in the 
epithelium and the connective tissue of phenytoin and in the control group in human 
samples. Interestingly, the phenytoin group had higher expression of LOXL2 in both the 
epithelium and the connective tissue (2). We therefore evaluated the expression of 
LOXL2 proteins in response to CCN2/CTGF (200 ng/ml) and the vehicle. Cell layers 
were extracted at 6 hours from human gingival fibroblasts and after lysing, the cells in 
sample buffer the protein was quantified using the Nano-Orange kit. An equal amount of 
protein was subjected to SDS-PAGE as represented in Figure 3 (A-C). Densitometric 
analysis of representative western blot images of LOXL2 expression in CTGF/CCN2 
and control group is shown in Figure 3D.  
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Figure 3:  CCN2/CTGF does not upregulate LOXL2 protein expression in human 
gingival fibroblasts.  
 
Subconfluent primary human gingival fibroblasts were cultured and placed in serum-free 
medium containing 0.1% bovine serum albumin (BSA) for 6 hr. CCN2/CTGF (200 
ng/ml) or vehicle (medium) were added and cultured for an additional six hours. Cell 
layers were extracted and subjected to Western blot analyses for LOXL2 and β-actin as 
a loading control. Figure 3 (A- C) represents Western blot from 3 different subjects. 
Data shown in Figure 3 D represents means taken from 3 different subjects and 3 
replicates per condition for every subject from 3 independent western blots. Fold 
change ± SE (n=3) p<0.05; *; Student’s t-test. From the result we can conclude no 
significant up-regulation of LOXL2 expression upon addition of CCN2/CTGF. 
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4.2 Lentiviral inhibition of LOXL2 mRNA & protein expression in human gingival 
fibroblasts 
 
To further investigate our previous results, we decided to inhibit the expression of 
LOXL2 mRNA and protein.  This will allow us to examine the functions of LOXL2 in 
human gingival fibroblasts. Primary human gingival fibroblasts cells were transduced 
with 2 different lentiviral constructs of LOXL2 {LOXL2shRNA (195), LOXL2 shRNA 
(193)}, or Non Target shRNA (control). Non-transduced cells were eliminated using 
puromycin, a selective reagent. Transduced cells were seeded in a 6-well plate. We 
therefore evaluated the expression of LOXL2 proteins in response to LOXL2 
{LOXL2shRNA (195), LOXL2 shRNA (193)}, or Non Target shRNA (control). mRNA 
expression of LOXL2 in human gingival fibroblasts was analyzed by subjecting this RNA 
to RT- qPCR (Figure 4 A and B). 
 Cell layers were extracted and the cells were lysed using sample buffer.  Protein 
was quantified using the Nano-Orange quantification kit. Equal amounts of protein were 
subjected to SDS-PAGE. Densitometric analysis of representative western blot image of 
LOXL2 expression. Lanes from two replicate cultures are shown (Figure 4 C and D).  
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Figure 4: Inhibition of LOXL2 expression at protein and mRNA 
 
 
Primary human gingival fibroblast cells were transduced with lentiviral particles 
containing 2 different Lentiviral constructs designed to knockdown {LOXL2 shRNA 
(195), LOXL2 shRNA (193)}. Non-transduced cells were eliminated by puromycin. 
Selected cells were seeded in 6-well plates. LOXL2 expression at the mRNA level using 
the Lentiviral construct and control were evaluated by RT- qPCR Figure 4 (A and B). 
We also collected protein samples under similar conditions and samples were subjected 
to Western blot analysis (n=3). Lanes from two replicate cultures are shown Figure 4 (C 
and D). Results indicate significant inhibition of LOXL2 expression at both the protein 
and the mRNA level. 
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4.3  Lentiviral inhibition of LOXL2 expression regulates cell proliferation 
independent of CCN2/CTGF 
     
To investigate the importance of LOXL2 in promoting cell proliferation, we knocked 
down LOXL2 expression in human gingival fibroblasts. Primary human gingival 
fibroblasts were transduced with lentiviral particles containing LOXL2 shRNA195, 
LOXL2 shRNA193, or Non Target shRNA (control). Non-transduced cells were 
eliminated using puromycin, a selective reagent. Transduced cells were seeded at 5000 
cells per well in 24-well plates on day -1 and the cell proliferation analysis was done 
after 24 hours from day 0 using a CyQUANT assay with and without CTGF/CCN2. This 
assay measures DNA accumulation over a 24-hour period as an index of cell 
proliferation. Data shown in Figure 5 (A-D) are presented as means taken from 3 
different subjects & 6 replicates per condition for every subject used ± SE (n=3) p<0.05; 
*; Student’s t-test. 
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Figure 5: Inhibition of LOXL2 expression regulates cell proliferation in primary 
human gingival fibroblasts independent of CTGF/CCN2 
 
Results indicate that LOXL2 knock-down using 2 different LOXL2shRNAs inhibits cell 
proliferation in primary gingival fibroblasts. Fold changes induced by LOXL2 knock-
down are indicated. Data is presented as means taken from 3 different subjects and 6 
replicates per condition for every subject used ± SE (n=3) p<0.05; *; Student’s t-test. 
The result demonstrates significant inhibition of cell proliferation upon LOXL2 
knockdown independent of CCN2/CTGF in primary human gingival fibroblast cells 
except in Figure 5 C, which shows there is an upregulation of cell proliferation upon 
addition of CCN2/CTGF. 
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4.4   Regulation of cell proliferation by shLOXL2 without stimulation of cell 
apoptosis 
 
 
To further investigate if knockdown of LOXL2 stimulates cell apoptosis we performed 
the activated caspase 3 assay. For this experiment primary gingival fibroblast cells were 
transduced with either of two different shLOXL2 lentivirus particles shLOXL2 (195), 
shLOXL2 (193) or shNontarget, in addition, a positive control for caspase activation 
consisted of non-transduced primary gingival fibroblasts subjected to 20 Gy of ionizing 
radiation as previously described by Wolf in 1999 and corresponding negative control 
was non-irradiated cells grown at the same time which represented in Figure 6. Cell 
layers were extracted after lysing the cells in sample buffer and protein was quantified 
using the Nano-Orange quantification kit. Equal amounts of protein were subjected to 
Western blot analysis for activated caspase 3.  
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Figure 6 
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Figure 6 shLOXL2 (193, 195) inhibits cells proliferation in human gingival 
fibroblast cells with minimal to no stimulation of cell apoptosis 
 
Results from western blot in Figure 6 of cell extracts subjected to active caspase-3 
indicate minimal to no stimulation of cell apoptosis upon LOXL2 knockdown, while the 
positive control of human gingival fibroblast cells subjected to 20 Gy radiation exhibited 
activated caspase- 3 as expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
		
45	
4.5  Lysyl oxidase like -2 plays a critical role in regulating cell proliferation in 
primary gingival fibroblast cells in long term cultures 
 The purpose of this experiment was to analyze the growth of primary human 
gingival fibroblasts once they are transduced with lentiviral particles containing 
shLOXL2 195, shLOXL2193, or shNontarget (control). For this experiment primary 
human gingival fibroblast cells from 3 different subjects were transduced with each of 
the lentiviral particles respectively. Non-transduced cells were eliminated using 
puromycin. Cells were then seeded at 5,000 cells per well in 24-well plates on day -1 
and the growth curve was analyzed for 7 days. The number of cells on day 0 were used 
to establish that the number of cells in the control and knock-down groups at the 
beginning of the experiment was equivalent. As we can see in Figure 7 (A and B), 
growth curves were plotted and analyzed for cells transduced with either shLOXL2 
(195,193) or shNontarget (control) in 3 different subjects by CyQUANT and cell counting 
technique for 7 days. Data represented in Figure 7 (C and D) are means of (n=3), *, 
p<0.05; ANOVA with Post Hoc t-test with Bonferroni correction. 
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Figure 7:  Lysyl oxidase like -2 plays a critical role in regulating cell proliferation 
in primary gingival fibroblast cells in long term cultures 
We can conclude from our results in Figure 7 (A and B) that lysyl oxidase like -2 
(LOXL2) plays a critical role in regulating cell growth in primary human gingival 
fibroblast cells. Data indicate that each shLOXL2195 and shLOXL2193 transduced 
human gingival fibroblast cells resulted in potent inhibition of growth compared to 
shNontarget. LOXL2 knockdown inhibits cell proliferation in human gingival fibroblasts 
long term in long term cultures. Data is presented in Figure 7 (C and D) are means ± 
SE (n=3), *, p<0.05; ANOVA with post hoc t-test with Bonferroni correction. Results 
from the average of 3 subjects show significant inhibition of cell proliferation.  
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4.6 LOXL2 regulates cell growth in primary human gingival fibroblast cells 
independent of CCN2/CTGF 
 
The purpose of this experiment was to analyze if CCN2/CTGF via LOXL2 had a role in 
regulating cell growth of primary human gingival fibroblasts. The cells were transduced 
with lentiviral particles containing shLOXL2195 as shown in Figure 8 A, shLOXL2193 in 
Figure 8 B, or shNontarget (control) with and without CCN2/CTGF respectively. For the 
experiment primary human gingival fibroblast cells were transduced. 5,000 cells per well 
were cultured in 24-well plates on day 1. Day 0 was the day after the cells were seeded 
in order to establish similar number of cells in the control and knock-down groups from 
the beginning of the experiment.  The growth curves were plotted for cells transduced 
with either shLOXL2195 and shLOXL2193 or shNontarget (control) with and without 
CCN2/CTGF in 3 different subjects individually as shown in Figure 8 (A and B). 
Furthermore, Figure 8 (C and D) represents the average of 3 subjects for each 
condition with both the cell counting and CyQUANT technique. 
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Figure 8: LOXL2 regulates cell growth in primary human gingival fibroblast cells 
independent of CTGF/CCN2 
 
We can conclude from our results Figure 8 (A and B) that both lysyl oxidase like- 2 
directed shRNA’s resulted in potent inhibition of growth compared to shNontarget 
(control) independent of CCN2/CTGF in human gingival fibroblast cells in long term cell 
cultures. Data presented as means ± SD (n=3), *, p<0.05; ANOVA with post hoc t-test 
with Bonferroni correction. In Figure 8 (C and D) data present are means of n=3 for 
each condition with both the cell counting and CyQuant techniques means ± SD (n=3), 
*, p<0.05; ANOVA with post hoc t-test with Bonferroni correction shows significant 
inhibition of cell proliferation independent of CCN2/CTGF. 
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4.7 Inhibition of enzymatic activity of LOXL2 inhibits cell proliferation in primary 
human gingival fibroblasts independent of CTGF/CCN2 at different concentration 
of pharmacological inhibitor (PXS-5033A) 
 
Primary human gingival fibroblast cells were cultured as described (Methods and 
Materials). In order to address whether LOXL2 stimulation of proliferation in human 
gingival fibroblast cells depends on its enzyme activity, effects of a novel and selective 
LOXL2 inhibitor PXS-5033A on gingival fibroblast proliferation was determined 
(Pharmaxis). Primary human gingival fibroblasts were seeded at 5,000 cells per well in 
24-well plate and then cells were replaced with serum free media for 16 hours. Followed 
by cells being treated with different concentrations of PXS-5033A up to 5 µM for 24 
hours.  
CyQUANT assay were performed after 24 hours of treating the cells using different 
concentrations of PXS-5033A as we can see in Figure 9 (A and B). This assay 
measures DNA accumulation over a 24-hour period as an index of proliferation in 
presence and absence of CTGF/CCN2. 
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Figure 9: Inhibition of enzymatic activity of LOXL2 inhibits cell proliferation in 
primary human gingival fibroblasts independent of CTGF/CCN2. 
 
Results indicate significant inhibition of cell proliferation upon inhibition of enzymatic 
activity of LOXL2 independent of CCN2/CTGF. The data presented are means taken 
from 3 different subjects and with 6 replicates for each condition per subject. Student’s 
t-test ± SE (n=3) p<0.05; *. Results from Figure 9 (A and B) indicate inhibition of 
LOXL2 enzymatic activity using a pharmacologic inhibitor significantly inhibits cell 
proliferation in primary gingival fibroblasts independent of CTGF/CCN2. 
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4.8 Inhibition of enzymatic activity of LOXL2 attenuates cell proliferation in 
primary human gingival fibroblasts in long term cultures 
 
Primary human gingival fibroblast cells were cultured in 24 well plates. The growth 
curves were plotted for cells treated either with the PXS-5033A (Pharmaxis) 5 µΜ or 
vehicle control for 7 days both in presence and absence of CCN2/CTGF. For this 
experiment 5,000 primary human gingival fibroblast cells per well were seeded on day 
1. Growth curve analysis was performed from day 0 using the CyQUANT assay and the 
cell counting technique each day for 7 days as shown in Figure 10 (A and C) whereas 
Figure 10 (B and D) represents average of 3 subjects. 
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Figure 10 A, B Inhibition of enzymatic activity of LOXL2 regulates cell growth in 
primary human gingival fibroblasts in long term cultures 
 
Data suggests that inhibition of enzymatic activity of lysyl oxidase like 2 (LOXL2) 
regulates cell growth in primary human gingival fibroblasts in the long term. Growth 
curves were plotted for cells treated either with the LOXL2 pharmacological inhibitor or 
vehicle control absence of CCN2/CTGF as shown in Figure 10 A. Growth curves were 
analyzed using both CyQUANT and cell counting technique. Data is presented as 
means ± SD n=3, *, p<0.05; ANOVA with Post Hoc t-test with Bonferroni correction. 
Furthermore, Figure 10 B represents the average from 3 subjects using both the cell 
counting and CyQUANT technique. We can conclude that enzymatic activity of LOXL2 
reduces cell growth by approximately 18%-20%. The lack of significant inhibition may 
be because of media containing 5% FBS. Presence of amine oxidases in the FBS 
(0926) may have oxidized the inhibitor over time.  
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Figure 10 B, D Inhibition of enzymatic activity of LOXL2 regulates cell growth in 
primary human gingival fibroblasts independent of CCN2/CTGF in long term 
cultures  
Primary human gingival fibroblast cells were cultured in 24 well plates. The growth 
curves were plotted for cells treated either with the PXS-5033A (Pharmaxis) 5 µΜ or 
vehicle control in the presence and absence of CCN2/CTGF for 7 days. Primary human 
gingival fibroblast cells were seeded at 5,000 cells per well on day 1. Growth curve 
analysis was performed from day 0 using the CyQUANT assay each day for 7 days as 
shown in Figure 10 B from 3 different subjects. Figure 10 D represents as average 
from 3 different subjects and we can see there is no significant inhibition of cell growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
		
78	
4.9 Recombinant LOXL2 protein promotes cell proliferation in primary human 
gingival fibroblasts.  
 
We further wanted to investigate if there is upregulation of cell proliferation in primary 
human gingival fibroblast cells upon addition of rLOXL2. 5,000 cells per well of primary 
human gingival fibroblasts were cultured in a 24 well plate on day 1. At day 0 media was 
replaced with a serum free media.  After 16 hour cells were treated with different 
concentrations of the active rLOXL2. Figure 11 shows the cell proliferation analysis was 
performed after 24 hours from day 0 using the CyQUANT assay. 
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Figure 11 
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Figure 11: Recombinant LOXL2 protein promotes cell proliferation in primary 
human gingival fibroblasts.  
 
Results indicate addition of active rLOXL2 upregulates cell proliferation in primary 
gingival fibroblasts. Data presented in Figure 11 is means taken from 3 different 
subjects and 3 replicates per condition in each subject. We can conclude from the 
results that there is a significant upregulation of cell proliferation upon addition of 
rLOXL2. ± SE (n=3) p<0.05; *; Student’s t-test.  
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4.10 LOXL2 is present extracellularly and regulates cell proliferation upon 
activation of PDGFRβ by PDGF ligands 
 
To evaluate if LOX or any of its family members are present extracellularly. In this 
experiment, conditioned media was collected from cultured primary human gingival 
fibroblast cells as shown in Figure 12 A. Samples were centrifuged to remove any cell 
debris. The supernatant was stored at -20°C prior to use. For protein analysis, the 
conditioned media was concentrated. Protein quantification was performed using Nano 
orange assay. Equal amounts of samples were loaded. Western blot was performed. 
Lysyl oxidase enzyme activity from LOX has been previously shown to stimulate smooth 
muscle cells and megakaryocyte proliferation by influencing PDGF signaling (21, 51). It 
is not known if LOXL2 has any effects on activation of PDGF receptors. Here we 
evaluated the effects of PXS-5033A, BAPN, and rLOXL2 on PDGFRβ phosphorylation 
of Tyr 751 which is required for stimulation of AKT signaling (21). The experiment was 
carried out in cells taken from 3 different subjects. In Figure 12 B human gingival 
fibroblasts were grown in 6-well plates to 80% confluency. The media was changed into 
serum free media containing either specific LOXL2 inhibitors PXS-5033A (Pharmaxis) 1 
µΜ, BAPN 5 µM, rLOXL2 1 µM or a control. The serum free media was changed to 
serum free media with or without PDGF-BB 25 ng/ml for 2 hours. Samples were 
collected and western blot analysis was performed. 
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Figure 12 A, B:  LOXL2 is present extracellularly and activates PDGFRβ by 
 PDGF-BB 
 
In human gingival fibroblast cells the data Figure 12 A indicates that LOXL2 and LOXL4 
are present extracellularly. The experiment was performed from the cells taken from 3 
different subjects. 
Result in Figure 12 B indicate that LOXL2 inhibition with specific inhibitors reduces 
PDGF-BB-induced activating phosphorylation of PDGFRβ, whereas rLOXL2 addition 
upregulated the phosphorylation of PDGFRβ. Data indicates that treatment of cells with 
LOXL2 strongly amplifies the phosphorylation of PDGFRβ Tyr751 in response to PDGF-
BB, while both PXS-5033A and BAPN inhibit this activating phosphorylation. 
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4.11 Inhibition of LOXL2 inhibits collagen accumulation in human gingival 
fibroblasts.  
 
 
To investigate the importance of LOXL2 in mediating CCN2/CTGF stimulated collagen 
accumulation by human gingival fibroblasts knockdown of LOXL2 by shRNA technology 
and LOXL2 pharmacological inhibitor (PXS5033A) was employed. It was reasoned that 
if LOXL2 promotes both cell proliferation and collagen cross-linking, then LOXL2 
knockdown would diminish the ability of gingival fibroblasts to deposit collagen. We 
performed the collagen accumulation assay in response to LOXL2 knockdown and in 
response to treatment of cultures with PXS5033A. Moreover, we assessed collagen 
accumulation in the presence of CCN2/CTGF in LOXL2 knockdown cells. LOXL2 
knockdown and PXS5033A itself blocks basal collagen accumulation and the addition of 
CCN2/CTGF did not enhance collagen accumulation. Data shows that LOXL2 shRNA 
diminished the accumulation of collagen and that the presence of CCN2/CTGF did not 
affect this outcome. This finding could be consistent with the notion that LOXL2 is 
downstream of CCN2/CTGF. This data from Figure 13 (A and B) suggests that in order 
to observe any effect of CCN2/CTGF on collagen accumulation, LOXL2 must be 
expressed. Moreover, the data confirms that knockdown or pharmacological inhibition of 
LOXL2 inhibits collagen accumulation as expected. 
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Figure 13: Inhibition of LOXL2 by shRNA and pharmacological inhibitor inhibits 
collagen accumulation in human gingival fibroblasts  
Effects of LOXL2 knockdown and inhibition of enzymatic activity with and without  
CCN2/CTGF on collagen accumulation. (A) LOXL2 shRNA transduced gingival 
fibroblasts were treated with or without +/-200 ng/ml CCN2/CTGF for 7 days in the 
presence or absence of LOXL2 inhibitor (PXS5033A) and collagen accumulation was 
determined by the Sirius Red assay. (B) Non-transduced gingival fibroblasts were 
treated with or without CCN2/CTGF in the presence of increasing concentrations of 
PXS-5033A and collagen accumulation was determined. Data Figure 13 (A and B) 
indicates that LOXL2 is required for collagen accumulation in the presence or absence 
of CCN2/CTGF and enzymatic activity of LOXL2 regulates collagen accumulation in 
primary gingival fibroblasts. Data is means taken from 3 different subjects and 3 
replicates per condition in each subject. ± SE (n=3) p<0.05; *; Student’s t-test.  
 
 
 
 
 
 
 
 
 
CCCC
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4.12 Recombinant LOXL2 increases collagen accumulation in cultures of human 
gingival fibroblasts.  
 
To investigate whether LOXL2 can actually modulate collagen accumulation by human 
gingival fibroblasts we carried out the collagen accumulation assay in the presence or 
absence of CCN2/CTGF in the presence of added recombinant LOXL2 protein at 
different concentrations. Data from Figure 14 shows that under these conditions LOXL2 
alone increases collagen accumulation. Data supports our hypothesis that LOXL2 
stimulates collagen accumulation. 
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Figure 14 A, B: Recombinant LOXL2 protein increases collagen accumulation by 
primary human gingival fibroblasts.  
 
After cultures of human gingival fibroblasts were confluent cells were cultured for an 
additional 7 days with 3 media changes. 50 µg/ml ascorbate was added with each 
media change. Cells were treated with either vehicle or active rLOXL2 enzyme at 
different concentrations. For each condition triplicates were used from each subject. 
Cultures were then fixed and stained with Sirius Red dye and the samples were eluted. 
Eluted dye was quantitated by measuring absorbance at 540 nm as described (35).  
(B) Quantitation of Sirius Red elution. Results indicate significant upregulation of 
collagen accumulation upon addition of rLOXL2. Data presented in Figure 14 B is 
means taken from 3 different subjects and 3 replicates per condition from each subject. 
± SE (n=3) p<0.05; *; Student’s t-test. 
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5. Discussion 
 
         Gingival overgrowth lesions occur as a side effect of different types of 
medications. These medications have completely different mechanism of action, but all 
lesions appear clinically similar. In the past, our laboratory has shown that these drugs 
do demonstrate differences at the cellular and biochemical levels among these gingival 
overgrowth subjects. The main mechanisms of drug-induced gingival overgrowth have 
not yet been discovered. However, studies on fibrotic gingival tissues have shown an 
increase in growth factors and cytokine levels (4, 37, 62, 64). Elevated TGF-β levels 
were found at the edge of the rete pegs in fibrotic gingival lesions, whereas 
CCN2/CTGF expression was found both at connective tissue and epithelial layers of the 
lesions (41). Interestingly, immune-histochemical analysis of LOXL2 expression in 
human phenytoin induced overgrowth samples in our laboratory revealed substantial 
over expression of LOXL2 in the epithelium and the connective tissue of human 
phenytoin induced overgrowth samples when compared to healthy control samples (2).   
        Many studies have been conducted to understand more about the multifunctional 
LOXL2 protein. LOXL2 plays a significant role in collagen cross-linking, fibrosis, 
angiogenesis, epithelial to mesenchymal transition, and cell proliferation (10). In the 
past, studies have shown that LOXL2 can oxidize lysine residues of collagen and in that 
respect is similar to LOX (85). The role of LOXL2 in cell proliferation and collagen 
accumulation is not completely understood. In this study, we investigated a possible 
mechanism of LOXL2 function in regulating cell proliferation and collagen accumulation 
in vitro using human primary gingival fibroblast cells. LOXL2 is highly associated with 
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carcinoma of the breast (5, 6) and is upregulated in colon, gastric, breast cancers, 
esophageal squamous cell carcinoma, and oral squamous cell carcinoma (6, 22, 45, 48, 
53, 70, 71).  A specific LOXL2 inhibitor, a monoclonal antibody, has been developed (7) 
and is currently in clinical trials for a number of fibrotic conditions and cancers (83). In 
our study we found another critical role of LOXL2; regulation of cell proliferation and 
extracellular matrix maturation in primary gingival fibroblasts. CCN2/CTGF is a 
matricellular protein that has been shown to upregulate several cellular responses such 
as proliferation, chemotaxis adhesion, migration, and the production of extracellular 
matrix (80). We further investigated whether CCN2/CTGF regulates cell proliferation in 
primary gingival fibroblasts and, if so, is it mediated by LOXL2. Our results show that 
CCN2/CTGF alone does not significantly upregulate cell proliferation in primary gingival 
fibroblast cells. Regulation is mediated primarily by LOXL2. Data shown in Figure 11 
indicates LOXL2 addition stimulated the cell proliferation of human primary gingival 
fibroblasts, while results from Figure 5 indicates LOXL2 knockdown or pharmacologic 
inhibition of enzymatic functions of LOXL2 as shown in Figure 9 significantly attenuated 
cell proliferation short term independent of CCN2/CTGF. Furthermore, we found in the 
long term there was inhibition of cell growth upon LOXL2 knockdown as shown in 
Figure 8, but there was only 18-20% inhibition when pharmacological inhibitor was 
used as shown in Figure 10. This may be due to the presence of other amine oxidases 
in FBS which may have oxidized the inhibitor over time and which may have led to long 
term loss of effect of the pharmacological inhibitor. From our result we can conclude 
that enzymatic functions of LOXL2 may be one of the regulators in regulating cell 
proliferation in primary gingival fibroblasts. 
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         In our present study we further found the presence of LOXL2 and LOXL4 
extracellularly in primary gingival fibroblasts as shown in Figure 12 A. LOXL4 has been 
found to share 51% to 54% amino acid identity with LOXL2 and LOXL3 respectively, but 
LOXL4 is encoded by a short exon which is not found in LOXL2 or LOXL3. These 
enzymes may also contribute to developmental regulation, senescence, tumor 
suppression, cell growth control, and chemotaxis (3). In addition, studies have shown 
that LOXL4 is secreted extracellularly and significantly contributes to ECM deposition in 
aortic endothelial cells (15).  Tumors from mucosal squamous epithelium have an 
overexpression of LOXL4 mRNA in HNSCC (25). Recent studies in the past have 
shown the upregulation of LOXL2 in phenytoin induced gingival overgrowth tissue (2). 
The role of extracellular LOXL2 in the development of the pathological 
microenvironment and the role of LOXL2 in reducing tumor progression in PyMT 
induced tumors or metastasis in MDA-MB-435 cells has also been reported (6, 7). We 
further investigated the mechanism by which LOXL2 regulates cell proliferation in 
primary gingival fibroblasts. Platelet-derived growth factor-α and -β receptors have 
been shown to be induced in the human gingival fibroblasts and periodontal ligament 
cells (26). Platelet-derived growth factor also initiates mitogenesis (65).  In searching for 
regulators of PDGF, a recent study found that LOX affects the binding of PDGF to 
PDGFR in vascular smooth muscle cells and subsequently enhances downstream 
proliferation signaling (51) similarly it is also present in megakaryocytes (21). We further 
investigated the possibility that extracellular LOXL2 oxidizes cell surface proteins, 
including the PDGF receptor-β (PDGFR-β), and affects PDGF-BB-induced regulation of 
cell proliferation in primary human gingival fibroblast cells. 
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         Results from our western blot analysis show that upon LOXL2 inhibition with 
specific inhibitors there is a reduction in PDGF-BB-induced phosphorylation of 
PDGFRβ, whereas addition of rLOXL2 upregulated the ligand-induced receptor 
activation as shown in Figure 12 B. We further looked into the effect on phosphorylation 
of PDGFRβ upon addition of rLOXL2 and rLOXL2 with pharmacological inhibitor or both 
in the presence and absence of rPDGFBB. Thereby, suggesting that lysyl oxidase like 2 
via PDGFR-β may be one of the responsible mechanisms in regulating cell proliferation 
in primary human gingival fibroblasts.  
        Furthermore, past studies have shown that CCN2/CTGF up-regulates collagen 
deposition in gingival tissue via α6β1 integrin interactions (30). Collagen biosynthesis is 
a complex process in which there is intracellular synthesis, modification, assembly of 
procollagen chains, secretion, processing by procollagen N- and C- proteinases, and 
lysyl oxidase-dependent cross-linking (73). LOX amine oxidase is a key enzyme for the 
cross-linking of collagen and elastin molecules resulting in solubilization and 
stabilization and which allows them to function in the extracellular matrix. The 
importance of LOX activity has been studied in great detail over the years in many 
tissues including cardiovascular tissue, bone, and skin (82). Our laboratory previously 
reported that lysyl oxidase activity was increased by CCN2/CTGF in gingival fibroblast 
cultures (35). Collagen deposition was increased in gingival fibroblasts by CCN2/CTGF 
without any increase in LOX mRNA levels, suggesting that collagen deposition was 
caused by post translational events (35). 
        Studies have also demonstrated that collagen crosslinks contribute to the 
mechanical strength and other properties of bone (47). Since lysyl oxidase mRNA levels 
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were not regulated by CCN2/CTGF, other isoforms of the more recently found LOXL 
genes may be responsible for the increased lysyl oxidase catalytic activity (20).  
         Akiri et al. have reported that LOXL2 could promote tumor fibrosis and tumor 
progression (16, 69). For the resolution of fibrosis importance of collagen remodeling 
has been demonstrated in models by inhibiting lysyl oxidase (LOX) family members (6). 
LOXL2 catalyzes the cross-linking of fibrillar collagen (18, 85). Increases in tissue 
tension by LOXL2 was found sufficient to reverse established fibroblast activation, TGF-
β signaling, cytokine production, inflammation, and other markers of pro-fibrogenic 
imbalance (7). Studies have also reported the participation of secreted LOXL2 in gastric 
carcinoma metastasis (71). To further investigate one of the mechanisms that may 
contribute to fibrotic changes in gingiva in response to systemic medications, like the 
anti-seizure drug phenytoin, the immunosuppressant cyclosporin A, and calcium 
channel blockers including nifedipine we inhibited the LOXL2 expression at both the 
basal and protein level.  After Sirius Red staining we found both shRNA-mediated 
knockdown and pharmacological inhibiton of LOXL2 significantly inhibits collagen 
accumulation in CCN2-treated and non-treated primary human gingival fibroblast 
cultures Figure 13 (A and B).  LOXL2 addition stimulated the collagen accumulation in 
cultures of human gingival fibroblast cells Figure 14 (A and B). From our results we can 
suggest that LOXL2 plays a critical role in contributing to collagen accumulation both in 
the presence and absence of CCN2/CTGF in primary human gingival fibroblasts in vitro. 
        Selective inhibition of LOXL2, which is over-expressed in both human fibrotic 
diseases and other pathologic conditions, may also constitute a potential therapeutic 
target in the future. We propose the development of an animal model that would be a 
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useful tool in developing a better understanding about the mechanism in its entirety. 
This will help us to know more about the pathogenesis of drug-induced gingival fibrosis 
and its treatment options to resolve the disease. Meller et al.  has shown that the Balb/c 
mouse was a good model and gingival changes could be observed within four weeks in 
response to cyclosporin A treatment (55). This study among others, including studies 
done in our laboratory, suggest that human and animal models can be compared.  
         In summary, we can conclude from our data that lysyl oxidase like 2 plays a 
critical role in promoting the proliferation of primary gingival fibroblast cells with minimal 
or no stimulation of cell apoptosis as shown in Figure 6. Furthermore, LOXL2 inhibition 
with specific inhibitors of LOXL2 catalytic activity reduces cell proliferation. One of the 
mechanisms by which LOXL2 may regulate cell proliferation is by PDGF-BB-induced 
phosphorylation of PDGFRβ. LOXL2 inhibition with specific inhibitors reduces PDGF-
BB-induced activating phosphorylation of PDGFRβ, whereas rLOXL2 addition up-
regulated ligand-induced receptor activation respectively by western blot as shown in 
Figure 12 B. This activity of lysyl oxidase like 2, which is targeted by PDGF, may be 
important in maintaining primary gingival fibroblast cells. In addition, we found shRNA-
mediated knockdown or pharmacological inhibition of LOXL2 blocked collagen 
accumulation in CCN2-treated and non-treated primary human gingival fibroblast 
culturesas shown Figure 13 (A and B) which was determined by Sirius Red staining. 
Results from DNA in cell layers shows that collagen accumulation is strongly diminished 
in cell layers and the addition of active LOXL2 in different concentrations in human 
gingival fibroblasts stimulated the differentiation into mature functional extracellular 
matrix producing connective tissue cells as shown in Figure 14 (A and B). These in 
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vitro findings suggests that LOXL2 may be one of the key regulators in controlling cell 
proliferation and collagen accumulation in primary human gingival fibroblasts. 
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6 Conclusion 
         From this in vitro study, we can conclude that LOXL2 plays a critical role in 
promoting cell proliferation and collagen maturation independent of CCN2/CTGF. The 
mechanism by which LOXL2 promotes proliferation may be by enhancing the 
phosphorylation of PDGFR beta Tyr751 in response to PDGF-BB. With further in vivo 
studies we may be able to strengthen our results we found from this in vitro study. 
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